Regulatory Post Marketing Surveillance Study on Nexavar
Phase of Trial: Phase IV
Latest Information Update: 22 Sep 2015
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer; Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Bayer
- 18 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Apr 2015 Planned End Date changed from 1 Jun 2015 to 1 Jul 2015, as reported by ClinicalTrials.gov.
- 24 Feb 2015 Planned End Date changed from 1 Dec 2014 to 1 Jun 2015 according to the ClinicalTrials.gov record.